VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2020 | Targeted therapies in combination with ruxolitinib

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, updates us on the use of novel targeted therapies in combination with ruxolitinib, a JAK inhibitor. These include results of the MANIFEST study (NCT02158858) combining a BET inhibtor with ruxolitinib in myelofibrosis, azaciditine with ruxolitinib, as well as studies evaluating the BCL-2 inhibitor, venetoclax in combination with JAK inhibition. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter